© Reuters.
© Reuters.

By Medha Singh

(Reuters) – U.S. stock index futures rose on Friday as Pfizer said it could apply for emergency use of its COVID-19 vaccine candidate as early as November, shaking off worries over a stand-off in Washington on more fiscal aid.

The drugmaker’s shares (N:) firmed 1% in premarket trading after it said it would file for U.S. emergency approval of its COVID-19 vaccine candidate being developed along with Germany’s BioNTech SE (F:) as soon as a safety milestone is achieved in the third week of November.

BioNTech’s U.S.-listed shares (O:) jumped 2.4%.

Trading on Wall Street this week has been dictated by news about more federal aid to help businesses and households reeling from the impact of the COVID-19 pandemic, with the S&P 500 on track for its smallest weekly gains in three.

Talks between Democrats and Republicans seemed unlikely to yield a deal before the Nov. 3 election at a time when data has underscored a struggling labor market and a stalling economic recovery.

President Donald Trump and Democratic challenger Joe Biden will return to the campaign trail with visits to three battleground states, a day after the two contenders clashed from afar during dueling televised town halls.

Meanwhile, after a mixed start to the third-quarter earnings season from the big Wall Street lenders, investors will look next week to results from Netflix Inc (O:), one of the technology mega-caps that have benefited from stay-at-home demand during the pandemic.

Analysts’ expectations for S&P 500 companies’ earnings have improved to an 18.8% fall from a 25% tumble forecast three months earlier.

Schlumberger (N:) dipped 0.4% ahead of its results scheduled before the opening bell.

At 6:35 a.m. ET, 1YMcv1> were up 55 points, or 0.19%, S&P 500 e-minis were up 6.5 points, or 0.19%, and were up 34.25 points, or 0.29%.

Gilead Sciences Inc (O:) slipped 1.3% as a World Health Organization study concluded its COVID-19 drug remdesivir does not help patients who have been admitted to hospital. Gilead has questioned the findings of the study.

Boeing Co (N:) rose 3.3% as a report said Europe’s aviation regulator had declared the U.S. planemaker’s 737 MAX safe to fly again.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Let’s block ads! (Why?)